Table 2 Response rates at the end of 4 cycles and the best response rates.

From: Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma

 

ICd(N = 31)

RCd(N = 32)

OR (95% CI)

P value

End of 4 cycles, n (%)

    

ORR

27(87.1)

23(71.9)

1.212 (0.938–1.565)

0.213

≥VGPR

7(22.6)

8(25.0)

0.903 (0.372–2.191)

0.822

CR + sCR

3(9.7)

3(9.4)

1.032 (0.225–4.370)

0.967

VGPR

4(12.9)

5(15.6)

  

PR

20(64.5)

15(46.9)

  

MR

2(6.5)

4(12.5)

  

SD

1(3.2)

4(12.5)

  

PD

1(3.2)

1(3.1)

  

Best response, n (%)

    

ORR

27(87.1)

23(71.9)

1.212 (0.938–1.565)

0.213

≥VGPR

13(41.9)

10(31.2)

1.342 (0.694–2.597)

0.439

CR + sCR

6(19.3)

5(15.6)

1.239 (0.421–3.645)

0.697

VGPR

7(22.6)

5(15.6)

  

PR

14(45.2)

13(40.6)

  

MR

2(6.5)

4(12.5)

  

SD

1(3.2)

5(15.6)

  

PD

1(3.2)

0

  

Abbreviations: ORR overall response rate; CR, complete response; sCR, stringent complete response; VGPR, very good partial response; PR, partial response; MR, minimal response; SD, stable disease; PD, progressive disease.